Key result
Clopidogrel therapy, alone or combined with ultralow-dose aspirin, was safe and resulted in similar survival to discharge and at 90 days compared with ultralow-dose aspirin alone in dogs with pIMHA.
Why the study?
Does clopidogrel alone or in combination with ultralow-dose aspirin improve survival to discharge and at 90 days in dogs with primary immune-mediated hemolytic anemia compared with ultralow-dose aspirin alone?
Population
24 client-owned dogs with primary immune-mediated hemolytic anemia able to tolerate oral medications and…
Comparison
Clopidogrel PO, alone or in combination with… vs Ultralow-dose aspirin alone PO
Design
Preclinical, randomized in 3 treatment groups, unmasked
Follow-up
90 days
Authors
Loading...
Supports safety of clopidogrel options in canine pIMHA without survival advantage; leaves open need for larger randomized trials.
RCT (n=24)
Open-label
3 treatment groups
Does clopidogrel alone or in combination with ultralow-dose aspirin improve survival to discharge and at 90 days in dogs with primary immune-mediated hemolytic anemia compared with ultralow-dose aspirin alone?
Clopidogrel therapy, alone or in combination with ultralow-dose aspirin, appears safe and yields similar short-term survival compared to aspirin alone in dogs with primary immune-mediated hemolytic anemia.
Mellett et al. (2010) conducted an RCT in Primary immune-mediated hemolytic anemia (pIMHA) in dogs (n=24). Clopidogrel alone or combined with ultralow-dose aspirin vs. Ultralow-dose aspirin alone was evaluated on Survival to discharge and at 90 days. Clopidogrel therapy, alone or combined with ultralow-dose aspirin, was safe and resulted in similar survival to discharge and at 90 days compared with ultralow-dose aspirin alone in dogs with pIMHA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: